Haemonetics - HAE Total Debt to Capital

Haemonetics Corporation (HAE) relies on predictable cash flows due to the critical importance of its products to medicine. This price action on GURU.Markets, where the indicator stands at 1.40, complements the profile of this global leader in blood collection, whose systems and software create a continuous profit generator. Strong pricing power allows the company to confidently raise prices on essential components.

To assess the resilience of Haemonetics Corporation (HAE) to market downturns, it is critical to understand the balance between borrowed funds and equity. Since the production of plasma collection systems and blood purification equipment requires capital expenditures, changes in the leverage ratio reflect the proportion of total liabilities to equity. An increase in this metric signals debt service risks, whereas low values confirm the business's financial autonomy.